baltimore conference logo
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

MET as a Secondary Driver in Lung Cancer

May 14, 2015
D. Ross Camidge, MD

Special Reports, NSCLC (Issue 7), Volume 7, Issue 2

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.

D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.

<<<

View more from the NSCLC Special Report